نتایج جستجو برای: infliximab

تعداد نتایج: 7105  

2017
Cheng-Chun Ji Shota Takano

BACKGROUND/AIMS Infliximab has proven to be effective in the treatment of perianal fistulas in Crohn's disease (CD) but the efficacy of adalimumab is still unclear. The aim of this study is to assess the clinical efficacy of adalimumab and compare the results with those for infliximab. METHODS Forty-seven CD patients treated for perianal fistulas with infliximab from September 2005 to Decembe...

2013
Adriane D. M. Vorselaars Elisabeth V. Sjögren Coline H. M. van Moorsel Jan C. Grutters

Introduction. Although the role of TNF- α in tumor development is not fully understood, an increased risk of malignancy with TNF- α -inhibitors, such as infliximab, has been suggested. Case Presentation. We present a 54-year-old nonsmoking female sarcoidosis patient. After seven months of infliximab therapy a T1aN0M0 larynx carcinoma of the right vocal cord was found and excised. Within a year,...

2016
Chang Hwan Choi In Do Song Young-Ho Kim Ja Seol Koo You Sun Kim Joo Sung Kim Nayoung Kim Eun Soo Kim Jae Hak Kim Ji Won Kim Tae Oh Kim Hyun Soo Kim Hyo Jong Kim Young Sook Park Dong Il Park Soo Jung Park Hyun Joo Song Sung Jae Shin Suk-Kyun Yang Byong Duk Ye Kang-Moon Lee Bo In Lee Sun-Young Lee Chang Kyun Lee Jong Pil Im Byung Ik Jang Tae Joo Jeon Yu Kyung Cho Sae Kyung Chang Seong Ran Jeon Sung-Ae Jung Yoon Tae Jeen Jae Myung Cha Dong Soo Han Won Ho Kim

PURPOSE Infliximab is currently used for the treatment of active Crohn's disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of response in Korean patients with CD. MATERIALS AND METHODS A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and fistulizing CD (n=86) or both (n=33) were rev...

Journal: :Acta dermatovenerologica Croatica : ADC 2009
Sandra Peternel Larisa Prpić-Massari Tina Guina Srdan Novak Ines Brajac Marija Kastelan

Infliximab is an anti-tumor necrosis factor-monoclonal antibody shown to be effective in the treatment of moderate-to-severe psoriasis and psoriatic arthritis. We report on the first two patients in Croatia in which the efficacy of infliximab therapy was monitored and evaluated primarily on the basis of cutaneous manifestations of psoriasis. Both patients had severe, treatment-resistant chronic...

2009
Young Kyung Yoon Jeong Yeon Kim Jang Wook Sohn Min Ja Kim Ja Seol Koo Jai Hyun Choi Dae Won Park

INTRODUCTION The use of the drug infliximab for the treatment of patients with Crohn's disease can be complicated by tuberculosis. A paradoxical reaction during antituberculosis chemotherapy and immunologic reconstitution after discontinuation of infliximab can result in severe disseminated tuberculosis. CASE PRESENTATION A 38-year-old Korean man with severe Crohn's disease presented with fev...

2007
Rebecca Grainger Andrew A Harrison

Ankylosing spondylitis (AS) is a chronic, progressive disease characterized by inflammation in the spine and sacroiliac joints which causes pain, stiffness and the potential for spinal ankylosis. It is associated with significant functional impairment. It is common and since onset is often in young people, the burden of disease is considerable. Conventional treatment including non-steroidal ant...

2016
Takuya Iwama Aki Sakatani Mikihiro Fujiya Kazuyuki Tanaka Shugo Fujibayashi Yoshiki Nomura Nobuhiro Ueno Shin Kashima Takuma Gotoh Junpei Sasajima Kentaro Moriichi Katsuya Ikuta

METHODS Pneumocystis carinii pneumonia occasionally appears in immunodeficient patients. While several reports have shown that Pneumocystis carinii pneumonia occurred in the early phase of starting infliximab treatment in patients with Crohn's disease (CD), the present case suggests for the first time that an increased dosage of infliximab may also lead to pneumonia. RESULTS A 51-year-old mal...

Journal: :Rheumatology 2012
Helena Canhão Ana Maria Rodrigues Ana Filipa Mourão Fernando Martins Maria José Santos José Canas-Silva Joaquim Polido-Pereira José Alberto Pereira Silva José António Costa Domingos Araújo Cândida Silva Helena Santos Cátia Duarte José Antonio Pereira da Silva Fernando M Pimentel-Santos Jaime Cunha Branco Elizabeth W Karlson João Eurico Fonseca Daniel H Solomon

OBJECTIVES Adalimumab, etanercept and infliximab are effective TNF inhibitors (TNFis) in the treatment of RA, but no randomized clinical trials have compared the three agents. Prior observational data are not consistent. We compared their effectiveness over 1 year in a prospective cohort. METHODS Analyses were performed on subjects' first episode of TNFi use in the Rheumatic Diseases Portugue...

2004
Janne S Suominen Yangyang Wang Antti Kaipia Jorma Toppari

Objective: Tumor necrosis factor-alpha (TNF-a) has been shown to inhibit germ cell death in human seminiferous epithelium. In the present study, we wanted to explore the effects of TNF-a in the rat seminiferous epithelium and to study molecular mechanisms of germ cell apoptosis. Furthermore, the effects of infliximab were studied. Infliximab is a TNF-a antagonist used in autoimmune disorders, s...

Journal: :Digestion 2004
Julia Seiderer Burkhard Göke Thomas Ochsenkühn

BACKGROUND Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD). Serious side-effects of such an immunomodulating therapy are speculated and therefore we reviewed our clinical experience in a retrospective safety study looking upon a single c...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید